A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer (Q65390278)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer |
clinical trial |
Statements
A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer. (English)
0 references
March 2006
0 references
October 2007
0 references
736
0 references
18 year
0 references